Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin J Am Soc Nephrol
Autors principals: Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W., Agarwal, Rajiv, Cannon, Christopher P., Capuano, George, Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Oh, Richard, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Jardine, Meg J., Perkovic, Vlado
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769025/
https://ncbi.nlm.nih.gov/pubmed/33214158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.10140620
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars